Recent News

• 09.24.2025 - Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
• 09.24.2025 - Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
• 09.08.2025 - Burning Rock Reports Second Quarter 2025 Financial Results
• 09.08.2025 - Burning Rock Reports Second Quarter 2025 Financial Results
• 06.06.2025 - Burning Rock Reports First Quarter 2025 Financial Results
• 06.06.2025 - Burning Rock Reports First Quarter 2025 Financial Results
• 03.25.2025 - Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
• 03.25.2025 - Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
• 12.31.2024 - Burning Rock Announces Results of 2024 Annual General Meeting
• 12.31.2024 - Burning Rock Announces Results of 2024 Annual General Meeting

Recent Filings

• 09.08.2025 - EX-99.1 EX-99.1
• 09.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.06.2025 - EX-99.1 EX-99.1
• 06.06.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.29.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.25.2025 - EX-99.1 EX-99.1
• 12.31.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.31.2024 - EX-99.1 EX-99.1